LAVA Therapeutics N.V. (LVTX)
|Net Income (ttm)||-16.57M|
|Trading Day||April 9|
|Day's Range||15.00 - 15.87|
|52-Week Range||9.76 - 17.20|
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T...
LAVA Therapeutics, a Dutch Phase 1/2a biotech developing novel bispecific antibodies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
LAVA Therapeutics N.V. has filed to go public with an IPO on the NASDAQ.
LAVA Therapeutics is a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Our approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by our bispecific gamma-delta T cell engagers, or gamma-delta bsTCEs. These cells have the natural ability to distinguish tumor cells from healthy cells. Activat... [Read more...]
|IPO Date |
Mar 25, 2021
|Stock Exchange |
|Ticker Symbol |